## WNK Inhibition Increases Surface Liquid pH and Host Defense in Cystic Fibrosis Airway Epithelia

Tayyab Rehman<sup>1</sup>, Philip H. Karp<sup>1,2</sup>, Andrew L. Thurman<sup>1</sup>, Steven E. Mather<sup>1</sup>, Akansha Jain<sup>1</sup>, Ashley L. Cooney<sup>3</sup>, Patrick L. Sinn<sup>3</sup>, Alejandro A. Pezzulo<sup>1</sup>, Michael E. Duffey<sup>4</sup>, and Michael J. Welsh<sup>1,2,5</sup>

<sup>1</sup>Department of Internal Medicine and <sup>3</sup>Department of Pediatrics, Pappajohn Biomedical Institute, <sup>5</sup>Department of Molecular Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, and <sup>2</sup>Howard Hughes Medical Institute, University of Iowa, Iowa City, Iowa; and <sup>4</sup>Department of Physiology and Biophysics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York

ORCID IDs: 0000-0001-7792-201X (T.R.); 0000-0003-2717-9138 (A.L.C.); 0000-0001-7544-5109 (A.A.P.).

#### Abstract

In cystic fibrosis (CF), reduced HCO<sub>3</sub><sup>-</sup> secretion acidifies the airway surface liquid (ASL), and the acidic pH disrupts host defenses. Thus, understanding the control of ASL pH (pH<sub>ASL</sub>) in CF may help identify novel targets and facilitate therapeutic development. In diverse epithelia, the WNK (with-no-lysine [K]) kinases coordinate  $HCO_3^-$  and Cl<sup>-</sup> transport, but their functions in airway epithelia are poorly understood. Here, we tested the hypothesis that WNK kinases regulate CF pH<sub>ASL</sub>. In primary cultures of differentiated human airway epithelia, inhibiting WNK kinases acutely increased both CF and non-CF pH<sub>ASL</sub>. This response was  $HCO_3^-$  dependent and involved downstream SPAK/OSR1 (Ste20/SPS1-related proline-alanine-rich protein kinase/oxidative stress responsive 1 kinase).

Importantly, WNK inhibition enhanced key host defenses otherwise impaired in CF. Human airway epithelia expressed two *WNK* isoforms in secretory cells and ionocytes, and knockdown of either *WNK1* or *WNK2* increased CF pH<sub>ASL</sub>. WNK inhibition decreased Cl<sup>-</sup> secretion and the response to bumetanide, an NKCC1 (sodiumpotassium-chloride cotransporter 1) inhibitor. Surprisingly, bumetanide alone or basolateral Cl<sup>-</sup> substitution also alkalinized CF pH<sub>ASL</sub>. These data suggest that WNK kinases influence the balance between transepithelial Cl<sup>-</sup> versus HCO<sub>3</sub><sup>-</sup> secretion. Moreover, reducing basolateral Cl<sup>-</sup> entry may increase HCO<sub>3</sub><sup>-</sup> secretion and raise pH<sub>ASL</sub>, thereby improving CF host defenses.

**Keywords:** cystic fibrosis; WNK kinases; airway surface liquid; anion transport; pH

Cystic fibrosis (CF) is an inherited, multisystem channelopathy caused by mutations in the *CFTR* (cystic fibrosis transmembrane conductance regulator) gene (1–3). Loss of CFTR protein function reduces anion secretion, disrupts epithelial function, and impairs airway host defense. These abnormalities result in chronic airway obstruction, inflammation, infection, tissue destruction, and bronchiectasis and limit the life span of affected individuals.

CFTR is an apical  $HCO_3^-$  and  $Cl^-$  channel (4–6). In airway epithelia, these transport activities control the acid-base balance and composition of the thin film

of liquid, the airway surface liquid (ASL), that covers the apical membrane. The ASL interfaces with the environment and mediates at least two vital respiratory host defenses (7–9). Mucociliary clearance uses gel-forming mucins to trap inhaled particles and ciliary beating to propel them out of the airways. Secreted antimicrobial

(Received in original form April 20, 2022; accepted in final form July 18, 2022)

<sup>3</sup>This article is open access and distributed under the terms of the Creative Commons Attribution License 4.0. For reprints, please e-mail Diane Gern.

Supported by the Cystic Fibrosis Foundation Harry Shwachman Clinical Investigator Award (T.R.); National Institutes of Health grants HL091842 and HL152960; the Cystic Fibrosis Foundation Research Development Program Iowa RDP; National Heart, Lung, and Blood Institute grant K01HL140261 and Cystic Fibrosis Foundation grant PEZZUL20A1-KB (A.A.P.); and the Howard Hughes Medical Institute (M.J.W.).

Author Contributions: T.R. and M.J.W. conceived and designed studies. T.R. and P.H.K. prepared epithelia for experiments. T.R. performed assays, with additional assistance from S.E.M. and A.J. for bacterial killing and ciliary beat frequency measurements, respectively. A.L.C. and P.L.S. contributed scRNA-seq data. T.R., A.L.T., A.A.P., and M.J.W. analyzed data. M.E.D. provided insightful discussions of results. T.R. and M.J.W. wrote the manuscript. All authors approved the manuscript.

Correspondence and requests for reprints should be addressed to Tayyab Rehman, M.D., Department of Internal Medicine, University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI 48109. E-mail: rehmant@med.umich.edu.

This article has a related editorial.

This article has a data supplement, which is accessible from this issue's table of contents at www.atsjournals.org.

Am J Respir Cell Mol Biol Vol 67, Iss 4, pp 491-502, October 2022

Copyright © 2022 by the American Thoracic Society

Originally Published in Press as DOI: 10.1165/rcmb.2022-0172OC on July 18, 2022

Internet address: www.atsjournals.org

peptides disrupt bacterial cell membranes and kill inhaled pathogens. An abnormally acidic pH of the ASL (pH<sub>ASL</sub>) resulting from reduced CFTR-mediated HCO<sub>3</sub><sup>--</sup> secretion impairs these respiratory defenses (10–18). Importantly, ASL alkalinization rescues these defects and may benefit individuals with CF independent of *CFTR* genotype (19–21).

Transepithelial  $HCO_3^-$  secretion is a complex process. Several studies have identified key apical and basolateral transporters involved in this process (11, 22–25); others have resolved tissue-specific and species–specific differences (26–28). However, the cellular and molecular mechanisms that regulate airway  $HCO_3^-$  secretion in humans remain incompletely defined. CF airways express apical  $HCO_3^-$  channels and transporters other than CFTR (8, 29). Thus, identifying mechanisms that regulate non-CFTR  $HCO_3^-$  secretion may suggest novel ways to increase CF pH<sub>ASL</sub>.

We considered that knowledge of HCO<sub>3</sub><sup>-</sup> transport in nonairway epithelia might yield insights relevant to CF airways. In several epithelia, the WNK (with-nolysine [K]) kinases act as key regulators of anion transport (30, 31). WNK kinases are serine/threonine protein kinases that modify surface expression or activity of membrane transporters. In the pancreas, which shares similarities with airway HCO<sub>3</sub><sup>-</sup> transport, WNK kinases control ductal  $HCO_3^-$  secretion (26, 32). In one study of mouse pancreatic duct, silencing of WNK kinases increased, and WNK expression decreased HCO3<sup>-</sup> secretion (33). In other reports, these kinases were shown to modulate CFTR  $HCO_3^-$  channel activity (34, 35) and membrane expression of SLC26 (solute carrier 26) family transporters (36). However, whether WNK kinases coordinate HCO<sub>3</sub><sup>-</sup> secretion across human airway epithelia remains poorly understood.

In this study, we tested the hypothesis that WNK kinases regulate CF  $pH_{ASL}$ . We studied primary cultures of differentiated human airway epithelia and applied pharmacologic and genetic interventions to elicit responses. Our results show that airway epithelia express two WNK isoforms, WNK1 and WNK2, in secretory cells and ionocytes. Importantly, reducing WNK kinase activity increases  $pH_{ASL}$  and enhances key respiratory host defenses that are otherwise impaired in CF.

### Methods

Additional details on materials and methods are in the data supplement.

#### **Cell Culture**

Airway epithelial cells were harvested from human lungs procured as postmortem specimens, as explants from patients undergoing lung transplant, or as lungs deemed unfit for transplant. Informed consent for use in research was obtained. All studies were approved by the University of Iowa Institutional Review Board. Proximal bronchi were dissected, cut into small pieces, and enzymatically digested. Epithelial cells were isolated and seeded without passage onto collagen-coated inserts (Costar, 3470; Falcon, 353180). Cell culture medium comprised a 1:1 mixture of Dulbecco's modified Eagle medium/F-12, supplemented with 2% Ultroser G (Sartorius). Epithelia were differentiated at the air-liquid interface for 3 weeks or more before assay (37). During the course of this study, new CF lung donors became scarce, partly due to more individuals taking highly active CFTR modulators. To manage this situation, epithelial cells from previous donors with CF cryopreserved at P0 were thawed and differentiated. Table E1 in the data supplement reports genotypes of CF donors included in this study. Whenever feasible, studies followed a paired design so that epithelia from the same donor were assaved under control and treatment conditions. In experiments shown in Figure 2B, differentiated airway epithelia were generated from cryostocks of transformed human airway epithelial cell lines NuLi-1 (wild-type [WT]/WT) and CuFi-4 (G551D/ $\Delta$ F508), as previously reported (38). These cell lines were used as additional models to test CFTR dependence of pH<sub>ASL</sub> responses evoked by inhibiting WNK kinases. To assess cytokineinduced responses, epithelia were treated with a combination of 10 ng/ml TNFa (R&D Systems) and 20 ng/ml IL-17 (R&D Systems). Both cytokines were added to the Ultroser G-supplemented basolateral media for 48 hours before assessments.

#### **Pharmacologic Reagents**

WNK463 and ivacaftor were purchased from Selleckchem. Other reagents were purchased from MilliporeSigma.

#### Single-Cell RNA-seq and Analysis

Cells for scRNA-seq (single-cell RNA sequencing) were obtained from primary cultures of human airway epithelia. The epithelia were grown at the air-liquid interface for 3 weeks or more before assay. The cell culture methods were the same as reported above. At the time of assessment, all epithelia were visibly dry on the apical side. Electrophysiologic assessments in Ussing chambers showed a mean basal transepithelial conductance (Gt) of 3.2 mS/cm<sup>2</sup>, resistance of 433.3  $\Omega$ .cm<sup>2</sup>, and short-circuit current (ISC) of 72.6 mA/cm<sup>2</sup>. These properties indicated well-differentiated, polarized epithelia performing electrogenic ion transport. Additional details about library preparation, sequencing methods, and bioinformatic analysis can be found in the supplement. The data are available in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database (GEO GSE159056).

#### Immunocytochemistry

Airway epithelia were washed, fixed, permeabilized, and immunostained to reveal WNK1 and WNK2 expression. See supplemental methods for details.

#### pH<sub>ASL</sub> Measurement

pH<sub>ASL</sub> was measured using a fluorescent ratiometric pH indicator, SNARF-1, conjugated to 70 kD dextran (Thermo Fisher Scientific). Additional details are reported in the supplement.

#### **Epithelial Host Defenses**

Several assays were performed to assess epithelial defense mechanisms. 1) ASL viscosity was measured using the fluorescence recovery after photobleaching method (12). 2) Liquid absorption was measured using the micropipette technique (39). 3) Ciliary beat frequency was measured using phase contrast microscopy. 4) ASL antimicrobial activity was assessed using bacteria-coated grids (13). Additional details on these assays are provided in the supplement.

#### siRNA Knockdown

Gene knockdown in primary CF airway epithelia was achieved as reported previously (40). siRNAs were obtained from Integrated DNA Technologies (negative control: IDT DS NC 1; *WNK1*: IDT hs.Ri.WNK1.13.2; *WNK2*: IDT hs.Ri.WNK2.13.3) and transfected into



**Figure 1.** Expression of WNK (with-no-lysine [K]) kinases in human airway epithelia. (*A* and *B*) Single-cell RNA-seq was performed on primary cultures of differentiated airway epithelia from donors without (n=4) and with cystic fibrosis (CF) [n=4; *see* Table E1 for cystic fibrosis transmembrane conductance regulator (CFTR) genotypes]. Dot plot showing cell type–specific expression of the four *WNK* isoforms, and *STK39* (serine/threonine kinase 39) and *OXSR1* (oxidative stress responsive kinase 1), which encode Ste20/SPS1-related proline-alanine-rich protein kinase (SPAK) and oxidative stress responsive 1 kinase (OSR1), respectively. *CDH1* (e-cadherin) is included as a reference epithelial gene. For each dot, the size represents the detection rate in a particular cell type, and the color represents average gene expression for cells in which gene was detected. Data for CF ionocytes is not shown, as these cells were not detected in three out of four CF epithelia. Also see Figure E2. (*C* and *D*) Confocal images showing WNK1 and WNK2 immunolocalization in non-CF and CF epithelia. Scale bar, 5 µm. For each panel, similar staining results were obtained in two different donors. RNA-seq = RNA sequencing; PNEC = pulmonary neuroendocrine cell.

dissociated primary airway epithelial cells using Lipofectamine RNAiMax (Invitrogen). Transfected cells were seeded onto collagencoated inserts (Costar, 3470) and differentiated at the air–liquid interface. pH<sub>ASL</sub> was measured at Day 6 or 7 after seeding. The efficiency of gene knockdown was assessed with RT-PCR.

#### **Electrophysiologic Studies**

Airway epithelia were mounted in modified Ussing chambers (Physiologic Instruments) and bathed in symmetric Krebs buffer solution. Epithelia were voltage clamped, followed by recording of the  $I_{SC}$  and  $G_t$ . See supplemental information for details.

#### **Bulk RNA-seq**

RNA isolation, library preparation, sequencing, and bioinformatics analysis were previously reported (41). RNA-seq data are available in the National Center for Biotechnology Information's GEO database (GEO GSE176121).

#### Real-Time PCR

The primer pairs used were as follows: WNK1, 5'-GCCGTCAGATCCTTAAAGGT C-3' and 5'-CCAGTAGGGCCGGTGAT AA-3'; WNK2, 5'-CATACCTGAAGCG GTTCAAGG-3' and 5'-CTTTTGGCAAA TGACGCTCTTT-3'; and SFRS9, 5'-TGCGTAAACTGGATGACACC-3' and 5'-CCTGCTTTGGTATGGAGAGTC-3'. See supplemental methods for details.

#### Statistics

Statistical significance testing was performed on GraphPad Prism 8 Software. Statistical tests included paired Student's *t* test for comparing two groups and one-way ANOVA with Tukey's multiple comparison test for comparing more than two groups. A *P* value of < 0.05 was considered significant.

#### Results

# Airway Epithelia Express WNK1 and WNK2

The four *WNK* isoforms are expressed in a tissue-specific manner (42, 43). However, their expression in human airways remains relatively unexplored. Recent scRNA-seq studies have revealed considerable cellular-level heterogeneity within airway epithelia with implications for ion transport (44–46). Notably, these studies have shown that secretory cells express nearly half the epithelial *CFTR* transcript, and the ionocytes, though rare, express the highest amount on a per-cell basis (44–47). These cell types also express basolateral transporters involved in  $HCO_3^-$  and  $Cl^-$  secretion.

To identify which WNK kinases might regulate anion transport across airway epithelia, we performed scRNA-seq. We studied primary cultures of differentiated airway epithelia from four different donors without CF and four different donors with CF and examined



**Figure 2.** WNK463 increases airway surface liquid pH (pH<sub>ASL</sub>). Human airway epithelia were exposed to either vehicle or WNK463 (10  $\mu$ M) for 2 hours, and pH<sub>ASL</sub> was measured using SNARF-1-dextran. (*A*) pH<sub>ASL</sub> responses in primary cultures of non-CF (*n*=7) and CF epithelia (*n*=8). (*B*) pH<sub>ASL</sub> responses in NuLi-1 (*n*=6) and CuFi-4 epithelia (*n*=6). Ivacaftor (10  $\mu$ M) was applied for 2 hours in combination with WNK463. (*C*) pH<sub>ASL</sub> response in primary CF epithelia in the presence of HCO<sub>3</sub><sup>-</sup>/CO<sub>2</sub> and after replacing HCO<sub>3</sub><sup>-</sup> with HEPES and removing CO<sub>2</sub> from the environment (*n*=4). (*D*) Time course of WNK463-evoked response in primary CF epithelia (*n*=5). (*E*) Schematic showing direct versus indirect modulation of membrane transporters by WNK kinases. (*F*) pH<sub>ASL</sub> response in primary CF epithelia after 2-hour exposure to rafoxanide, a SPAK/OSR1 inhibitor (*n*=4). In *B*, each data point is an epithelium derived from either NuLi-1 or CuFi-4 cells. In all other cases, each data point represents a primary differentiated airway epithelium from a different human donor. Data are shown as mean ± SEM. Statistical significance was tested using two-way ANOVA with two-stage Benjamini, Krieger, and Yekuteli false discovery rate procedure for *A*, and ANOVA with *post hoc* Tukey's test for *B*, *C*, *D*, and *F*. \**P*<0.05, \*\*\**P*<0.001, and \*\*\*\**P*<0.001. Veh = vehicle.

cell type-specific WNK gene expression (Figures 1A and 1B). WNK1 was broadly expressed in all major cell types (i.e., secretory cells, ciliated cells, and basal cells), as well as ionocytes. WNK2 was also abundantly expressed in secretory cells and ionocytes. In contrast to WNK1, WNK2 was rarely detected in ciliated or basal cells. The remaining WNK isoforms, WNK3 and WNK4, were either not expressed, or expressed at a very low level. Importantly, WNK genes showed similar expression in CF versus non-CF epithelia (Figure E2). We also studied the expression of the two main downstream kinases (i.e., STK39, which encodes Ste20/SPS1-related prolinealanine-rich protein kinase [SPAK], and OXSR1, which encodes oxidative stress responsive 1 kinase [OSR1]). Both genes were broadly expressed and abundantly detected in secretory cells as well as ionocytes.

To reveal WNK protein expression, we immunolabeled non-CF and CF epithelia for WNK1 and WNK2 (Figures 1C and 1D). In agreement with scRNA-seq results, we detected WNK1 in ciliated as well as nonciliated cells and WNK2 predominantly in nonciliated cells. Further immunolocalization studies revealed WNK1 and WNK2 expression in secretory cells (labeled with anti-CC10 antibody) as well as ionocytes (labeled with anti-BSND antibody). Overall, these studies identified two WNK kinases in airway cells that secrete anions.

#### WNK Inhibition Increases CF pH<sub>ASL</sub>

Several HCO<sub>3</sub><sup>-</sup> and H<sup>+</sup> transport mechanisms integrate to determine pH<sub>ASL</sub>, and  $pH_{ASL}$  influences host defense (13, 19). To begin to understand the role of WNK kinases in regulating pHASL, we used pharmacologic WNK inhibition. WNK463 is a selective, ATP-competitive, pan-WNK kinase inhibitor and has recently emerged as a useful tool for studying ion transport physiology (48-51). We exposed airway epithelia to either vehicle or WNK463 for 2 hours and measured pHASL in an environment containing 25 mM HCO<sub>3</sub><sup>-</sup> and 5% CO<sub>2</sub>. In primary cultures of both CF and non-CF epithelia, WNK463 increased pHASL (Figure 2A). As an additional test, we also studied NuLi-1 (WT/WT) and CuFi-4  $(G551D/\Delta F508)$  epithelia and found that WNK463 elicited similar responses (Figure 2B). Alkalinization in CF epithelia indicated that the WNK463-induced response did not require CFTR. However, exposure of WNK463-treated CuFi-4 epithelia to ivacaftor



**Figure 3.** WNK463 enhances CF host defenses. Primary cultures of differentiated CF airway epithelia were treated with either vehicle or WNK463 (10  $\mu$ M). All treatments were for 2 hours except *B*, where it was for 4 hours. (*A*) ASL viscosity ( $\tau_{ASL}/\tau_{saline}$ ) in primary CF epithelia (n=5). The dashed horizontal line indicates the viscosity of saline. (*B*) Rate of apical liquid absorption in primary CF epithelia (n=6). The dashed horizontal line at 0 indicates no net secretion or absorption. (*C*) Ciliary beat frequency (CBF) in primary CF epithelia (n=11). (*D*) ASL killing activity against *Staphylococcus aureus* in primary CF epithelia (n=5). Each set of two data points with a connecting line represents epithelia from a different donor. Data are shown as mean ± SEM. Statistical significance was tested using paired Student's *t* test. \*P < 0.05 and \*\*P < 0.01. Veh = vehicle.

further increased  $pH_{ASL}$ . Ivacaftor increases open-state probability and function of CFTR-G551D channels. We concluded that inhibiting WNK supports ASL alkalinization through CFTR-independent as well as CFTRdependent mechanisms.

To further characterize the WNK463induced response, we performed additional studies in primary differentiated airway epithelia. When these epithelia were exposed to WNK463 in a nominally  $HCO_3^{-}/CO_2^{-}$ free environment, the pHASL response disappeared (Figure 2C). This result suggested that WNK463 increased CF pH<sub>ASL</sub> by increasing HCO<sub>3</sub><sup>-</sup> secretion and not by decreasing H<sup>+</sup> secretion. Next, we asked whether this response was time and dose dependent. Two hours of exposure increased pHASL, and continued exposure up to 24 hours did not further alkalinize ASL (Figure 2D). Moreover, 10 µM WNK463 alkalinized but a lower dose (1 µM) did not alter pH<sub>ASL</sub> (Figure E3).

WNK kinases modulate membrane transporters either directly or indirectly through their native substrates, SPAK and OSR1 (52) (Figure 2E). In scRNA-seq data, cell types expressing *WNK1* and *WNK2* also expressed genes encoding SPAK and OSR1. To test the latter's involvement in controlling  $pH_{ASL}$ , we treated CF epithelia with rafoxanide, an allosteric SPAK/OSR1 inhibitor (53). Similar to WNK463, rafoxanide applied for 2 hours also increased CF  $pH_{ASL}$  (Figure 2F). Taken together, these responses suggested that CF  $pH_{ASL}$  is controlled by upstream as well as downstream kinases in the canonical WNK/SPAK/OSR1 signaling pathway.

#### WNK463 Enhances CF Host Defenses

Previous studies showed that alkalinizing CF ASL improves respiratory host defenses (12, 19–21). Because WNK463 increased pH<sub>ASL</sub>, we tested its impact in CF epithelia. Defective mucus transport is a key feature of CF (54). In primary cultures of differentiated CF epithelia, WNK463 decreased ASL viscosity (Figure 3A), consistent with previous studies showing that increasing pH<sub>ASL</sub> decreases viscosity. In addition, WNK463 did not alter the rate of apical liquid absorption (Figure 3B), suggesting that a change in apical fluid volume was not involved. WNK463 also

increased ciliary beat frequency, albeit modestly (Figure 3C). Both decrease in viscosity and increase in ciliary beat frequency would improve CF mucus transport. Previous studies also indicated that CF ASL has reduced antibacterial activity (13, 55). WNK463 increased ASLmediated *Staphylococcus aureus* killing in primary CF epithelia (Figure 3D). Overall, these results suggested that targeting WNK kinase signaling may at least partially rescue CF host defense defects.

#### Either WNK1 or WNK2 Knockdown Increases CF pH<sub>ASL</sub>

WNK463 is a pan-WNK kinase inhibitor (48). Because airway epithelia expressed two WNK kinases, we asked whether WNK1 or WNK2 controlled CF pHASL. To test, we performed siRNA-mediated gene knockdown. Reducing either WNK1 or WNK2 expression increased CF pHASL (Figures 4A-4D). This result suggested that both isoforms, WNK1 and WNK2, participate in regulating CF pHASL. Although analyses of additive and compensatory effects of WNK1 and WNK2 would require single- and double-knockout experiments rather than knockdown experiments, these knockdown studies suggest that if compensatory effects exist, they are incomplete.

#### WNK463 Reduces Electrogenic Cl<sup>-</sup> Secretion

CFTR is the main route for anion exit across the apical membrane of airway epithelia. Whether WNK inhibition alters CFTR activity in airway epithelia is not well established. To test, we exposed non-CF epithelia to WNK463 for 2 hours and assayed in Ussing chambers containing symmetric Krebs solution (118 mM Cl<sup>-</sup> and 25 mM  $HCO_3^-$ , gassed with 5%  $CO_2$ ). After clamping transepithelial voltage, we recorded ISC and Gt and elicited responses to selective channel inhibitors or activators (Figures 5A and 5B). We added amiloride followed by DIDS (4,4 -diisothiocyano-2,2 stilbenedisulfonic acid) to abolish ENaC (epithelial Na<sup>+</sup> channel)-mediated Na<sup>+</sup> absorption and CaCC (Ca<sup>2+</sup>-activated Cl<sup>-</sup> channel)-mediated anion secretion, respectively. Next, we added forskolin to increase cellular cAMP and thereby phosphorylate and activate CFTR channels. We concluded with CFTR<sub>inh</sub>-172, an inhibitor of CFTR. We assessed the response to CFTR<sub>inh</sub>-172 and used it to estimate CFTR channel activity. WNK463 reduced



**Figure 4.** *WNK1* and *WNK2* regulate CF pH<sub>ASL</sub>. siRNAs were used to knock down gene expression in primary CF epithelia, and pH<sub>ASL</sub> was measured using SNARF-1-dextran. Knockdown efficiency was assessed using qRT-PCR. (*A* and *B*) Knockdown of *WNK1* (n=5). (*C* and *D*) Knockdown of *WNK2* (n=6). Each data point represents an epithelium from a different donor. Statistical significance was tested using paired Student's *t* test. \**P*<0.05 and \*\**P*<0.01. NC = negative control.

 $\label{eq:linear} \begin{array}{l} \Delta I_{SC}\mbox{-}CFTR \mbox{ by $\sim$50\%$ (Figure 5C).} \\ However, $\Delta G_t\mbox{-}CFTR \mbox{ remained unchanged}$ (Figure 5D). This result suggested that WNK463 decreased CFTR-mediated anion transport but did not alter CFTR channel activity at the apical membrane. \end{array}$ 

CF epithelia lack functional CFTR channels but express CaCC. Accordingly, we studied the effect of WNK463 on CaCCmediated anion transport in CF epithelia (Figures 5E and 5F). After blocking ENaC with amiloride, we added uridine triphosphate, a P2Y2 purinergic receptor agonist that increases cytosolic  $[Ca^{2+}]$  and thus activates CaCC. Next, we added DIDS, a nonspecific CaCC inhibitor, and recorded the change in ISC and Gt. WNK463 decreased DIDS-sensitive  $\Delta I_{SC}$  but slightly increased DIDS-sensitive  $\Delta G_t$  (Figures 5G and 5H). Together, these findings suggested that inhibiting WNK kinases reduces anion secretion, but the effect is not on apical anion channels.

To separate the effects of WNK inhibition on Cl<sup>-</sup> versus  $HCO_3^-$  transport, we repeated the studies in single anion solutions. In symmetric  $HCO_3^-$ -free solution, WNK463 reduced  $\Delta I_{SC}$ -CFTR (Figure 51); however, in Cl<sup>-</sup>-free solution,  $\Delta I_{SC}$ -CFTR remained unchanged. Similar results were obtained for the DIDS-sensitive  $\Delta I_{SC}$  in CF epithelia (Figure 5J). These data suggested that WNK inhibition reduces electrogenic Cl<sup>-</sup> secretion but does not alter electrogenic HCO<sub>3</sub><sup>-</sup> secretion.

#### Reducing Basolateral CI<sup>-</sup> Entry Increases CF pH<sub>ASL</sub>

Transcellular Cl<sup>-</sup> secretion involves the movement of Cl<sup>-</sup> across the apical and the basolateral membranes in series. Because studies of electrically conductive anion transport showed reduced Cl<sup>-</sup> secretion without major effects at the apical membrane, we asked whether a change at the basolateral membrane was involved. The loop-sensitive NKCC ( $Na^+$ - $K^+$ -2 Cl<sup>-</sup>) cotransporter is the main route for Cl<sup>-</sup> entry across the basolateral membrane, and WNK kinases are known to increase NKCC activity in renal epithelia (56, 57). To further investigate the effect of WNK463 on this transport mechanism, we studied non-CF and CF epithelia in Ussing chambers. After blocking ENaC with amiloride, we added either forskolin to activate CFTR in non-CF epithelia, or uridine triphosphate to activate

CaCC in CF epithelia. To estimate the contribution of NKCC1(sodium-potassium-chloride cotransporter 1), we added basolateral bumetanide and measured  $\Delta I_{SC}$ . WNK463 reduced bumetanide-sensitive  $I_{SC}$  in both non-CF and CF epithelia (Figures 6A and 6B). This result pointed to the involvement of WNK kinases in controlling basolateral Cl<sup>-</sup> uptake through a bumetanide-sensitive mechanism.

Previous studies in airway epithelia showed that bumetanide decreases intracellular  $[Cl^-]$  (58–60). This led us to hypothesize that lowering intracellular [Cl<sup>-</sup>] might also increase CF pHASL. To test, we performed two experiments: 1) We tested the effect of NKCC1 inhibition in CF epithelia. Exposure to bumetanide increased CF pHASL (Figure 6C, left panel). 2) We measured pH<sub>ASL</sub> in a Cl<sup>-</sup>-free environment. Similar to bumetanide, the removal of basolateral Clalso increased CF pH<sub>ASL</sub> (Figure 6C, right panel). Because WNK463 reduced bumetanide-sensitive ISC, and lowering NKCC1 activity or intracellular [Cl<sup>-</sup>] increased pHASL, we considered whether intracellular  $[Cl^-]$  was involved in the response evoked by WNK463. When introduced in the absence of Cl<sup>-</sup>, WNK463 failed to alkalinize CF ASL, thus indicating that the WNK463-elicited pHASL response was  $Cl^{-}$  dependent (Figure 6D).

## WNK463 Further Increases $pH_{ASL}$ in TNF $\alpha$ /IL-17-treated CF Epithelia

Airway inflammation is ubiquitous in individuals with CF after the first few weeks of life (61-63). The CF airway inflammation is characteristically neutrophil predominant, may develop in the absence of infection, and is further exacerbated by infection and colonization. Two CF-relevant inflammatory cytokines, TNFα and IL-17, drive neutrophilic inflammation (64-67). In previous work, combined TNFa/IL-17 increased HCO3<sup>-</sup> secretion and CF pHASL by increasing pendrin expression (41, 68). We asked if TNFa/IL-17-induced alkalinization was also accompanied by altered expression of WNK kinases. In gene expression studies, TNFα/IL-17 modestly reduced WNK1 and markedly reduced WNK2 expression (Figures 7A and 7B). In immunocytochemistry studies, TNFa/IL-17 decreased WNK2 detection, but WNK1 remained unchanged (Figures 7C and 7D). This led us to hypothesize that residual WNK kinases might continue to regulate  $HCO_3^{-}$  secretion in cytokine-treated



**Figure 5.** Effect of WNK463 on electrogenic Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup> secretion. Primary cultures of differentiated airway epithelia were treated with either vehicle (DMSO) or WNK463 (10  $\mu$ M) for 2 hours. Epithelia were mounted in Ussing chambers and short-circuit current (I<sub>SC</sub>) and basal transepithelial conductance (G<sub>t</sub>) were recorded as agents were sequentially added to the apical side. (*A* and *B*) I<sub>SC</sub> and G<sub>t</sub> in non-CF epithelia (*n*=5). (*C* and *D*)  $\Delta$ I<sub>SC</sub> and  $\Delta$ G<sub>t</sub> with addition of CFTR<sub>inh</sub>-172 in non-CF epithelia (*n*=5). (*E* and *F*) I<sub>SC</sub> and G<sub>t</sub> in CF epithelia (*n*=7). (*G* and *H*)  $\Delta$ I<sub>SC</sub> and  $\Delta$ G<sub>t</sub> with addition of apical DIDS (4,4'-diisothiocyano-2,2'-stilbenedisulfonic acid) in CF epithelia (*n*=7). Studies in *A*-*H* were performed with symmetric buffers containing both Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup>. (*I* and *J*) To separate the effect of WNK463 on electrogenic Cl<sup>-</sup> versus HCO<sub>3</sub><sup>-</sup> transport, Ussing chamber studies were repeated with HCO<sub>3</sub><sup>-</sup>-free or Cl<sup>-</sup>-free solutions. (*I*) shows  $\Delta$ I<sub>SC</sub> response with addition of CFTR<sub>inh</sub>-172 in non-CF epithelia (*n*=4-7), and (*J*) shows  $\Delta$ I<sub>SC</sub> response with apical DIDS in CF epithelia (*n*=5-6). Each data point represents an epithelium from a different donor. Data are shown as mean ± SEM. In some cases, error bars are hidden by symbols. Statistical significance was tested using paired Student's *t* test. \**P*<0.05. Veh = vehicle.

epithelia. Accordingly, exposure to WNK463 further increased pH<sub>ASL</sub> in CF epithelia treated with TNF $\alpha$ /IL-17 (Figure 7E). Because WNK463 decreased Cl<sup>-</sup> secretion, and reducing basolateral Cl<sup>-</sup> entry increased CF pH<sub>ASL</sub>, we predicted a similar response to lowering basolateral Cl<sup>-</sup> entry in cytokine-

treated CF epithelia. Exposure to bumetanide further alkalinized ASL in TNF $\alpha$ /IL-17–treated CF epithelia (Figure 7F). This result suggested that TNF $\alpha$ /IL-17 shifted apical anion secretion in favor of HCO<sub>3</sub><sup>-</sup> over Cl<sup>-</sup>, and lowering basolateral Cl<sup>-</sup> entry further augmented this response.

#### Discussion

Our transcript and immunocytochemistry data for *WNK1* and *WNK2*, and their substrates *STK39* and *OXSR1*, indicated that these kinases are expressed in secretory cells and ionocytes, the main airway epithelial



**Figure 6.** Reducing Cl<sup>-</sup> transport increases CF pH<sub>ASL</sub>. (*A* and *B*) Primary cultures of differentiated airway epithelia were treated with either vehicle or WNK463 (10  $\mu$ M) for 2 hours and assayed in Ussing chambers filled with symmetric Krebs buffer containing both Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup>. During I<sub>SC</sub> recording, amiloride was added to inhibit ENaC (epithelial Na<sup>+</sup> channel), followed by forskolin (non-CF) or UTP (uridine triphosphate) (CF) to maximally activate CFTR or CaCC (Ca<sup>2+</sup>-activated Cl<sup>-</sup> channel), respectively. At this point, basolateral bumetanide was introduced, and  $\Delta$ I<sub>SC</sub> was recorded (*n*=6 different non-CF, or 9 different CF donors). (*C*) Left panel: CF pH<sub>ASL</sub> response 2 hours after exposure to basolateral bumetanide (*n*=6 different donors); right panel: CF pH<sub>ASL</sub> in the presence or absence of basolateral Cl<sup>-</sup> (*n*=6 different donors). (*D*) CF pH<sub>ASL</sub> response in epithelia exposed to WNK463 (10  $\mu$ M) for 2 hours in the presence or absence of basolateral Cl<sup>-</sup> (*n*=6 different donors). Data are shown as mean ± SEM. Statistical significance was tested using paired Student's *t* test. \**P*<0.05 and \*\**P*<0.01. Burnett = basolateral bumetanide.

cells that secrete anions. Consistent with that localization, pharmacologically inhibiting WNK kinases, SPAK/OSR1 kinases, and knocking down *WNK1* and *WNK2* transcripts increased  $pH_{ASL}$ . These results thus identified an important role for WNK kinases in regulating  $HCO_3^-$  secretion across airway epithelia. Figure 8 shows a tentative model for how WNK1 and WNK2 may influence Cl<sup>-</sup> and  $HCO_3^-$  secretion and the ratio between the two transport processes in CF airway epithelia. Some features in this model are unknown at present and are an opportunity for future research.

Electrophysiological studies indicated that inhibiting WNK kinases decreased the Cl<sup>-</sup>-mediated, but not HCO<sub>3</sub><sup>-</sup>-mediated current. Moreover, ASL alkalinization persisted in the absence of CFTR activity in CF epithelia. A clue to a potential mechanism came with the finding that inhibiting WNK kinases largely eliminated the inhibitory effect of basolateral bumetanide on  $I_{SC}$ . Bumetanide inhibits NKCC1, the major pathway for Cl<sup>-</sup> entry into the cell, and thereby reduces the intracellular [Cl<sup>-</sup>] (58–60). Further evidence implicating intracellular [Cl<sup>-</sup>] came from studies showing that adding bumetanide alone or removing Cl<sup>-</sup> from the medium also alkalinized ASL in CF epithelia.

These results suggest that WNK kinases may play a key role in determining the balance between Cl<sup>-</sup> secretion and HCO<sub>3</sub><sup>-</sup> secretion across airway epithelia (Figure 8). Inhibiting WNK kinases decreased NKCC1 activity, which decreased Cl<sup>-</sup> secretion, increased HCO3<sup>-</sup> secretion, and increased pH<sub>ASL</sub>. The inference that inhibiting WNK reduces NKCC1 activity is supported by the finding that bumetanide also increased pH<sub>ASL</sub> and previous reports that WNK kinases increase NKCC activity in nonairway epithelia (56, 57). However, the mechanism that increases  $HCO_3^-$  secretion is uncertain. One possibility is that WNK inhibition reduces the intracellular [Cl<sup>-</sup>], thereby

increasing the driving force for Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange at the apical membrane and hence HCO<sub>3</sub><sup>-</sup> secretion. Finding that bumetanide replicates the effect of WNK inhibition on pH<sub>ASL</sub> is consistent with this hypothesis. However, Cl<sup>-</sup>-free bathing solution also induced HCO<sub>3</sub><sup>-</sup> secretion despite the fact that reduced [Cl<sup>-</sup>] would initially and transiently drive Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange in the opposite direction, and over the 2-hour time course of the experiment, cellular Cl<sup>-</sup> would be largely depleted. Thus, we favor an alternative explanation that intracellular Cl<sup>-</sup> is a signaling molecule that regulates membrane transport (69).

Intracellular [Cl<sup>-</sup>] regulation of HCO<sub>3</sub><sup>-</sup> secretion has been reported previously. A Cl<sup>-</sup>-sensing motif has been identified in some HCO<sub>3</sub><sup>-</sup> transporters and other proteins (35, 70). Low intracellular [Cl<sup>-</sup>] was shown to increase IRBIT (IP3 receptor binding protein released with IP3)stimulated NBCe1-B (electrogenic sodium bicarbonate cotransporter 1) activity (70). Kim and colleagues showed that low intracellular [Cl<sup>-</sup>] enabled structural association between WNK1 and CFTR and increased CFTR HCO<sub>3</sub><sup>-</sup> channel activity (35). Notably, this effect did not depend on WNK1 kinase activity. Yamaguchi and colleagues developed a computational model of guinea pig pancreatic duct HCO<sub>3</sub><sup>-</sup> secretion (71). In this model, maximal  $HCO_3^-$  secretion did not depend on an increase in CFTR HCO<sub>3</sub><sup>-</sup> permeability or a change in SLC26 Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange stoichiometry, but instead depended on suppression of basolateral Cl<sup>-</sup> uptake. The addition of NKCC1, normally missing from guinea pig pancreatic ducts, increased intracellular [Cl<sup>-</sup>] and reduced secreted [HCO<sub>3</sub><sup>-</sup>]. Our results also support intracellular [Cl<sup>-</sup>]-dependent regulation of  $HCO_3^{-}$  secretion. It will be important for future studies to establish underlying molecular mechanisms in airway epithelia.

We previously reported that combined TNF $\alpha$ /IL-17 increased production of pendrin, an apical Cl<sup>-</sup>/ HCO<sub>3</sub><sup>-</sup> exchanger, and alkalinized CF ASL (41, 68). Here, we show that TNF $\alpha$ /IL-17 also reduced WNK2 expression. Moreover, inhibiting the residual WNK kinase activity with WNK463 further increased pH<sub>ASL</sub>, and basolateral bumetanide mimicked the effect of WNK inhibition. These proinflammatory cytokines may thus induce HCO<sub>3</sub><sup>-</sup> secretion and increase pH<sub>ASL</sub> by at least two mechanisms, increasing pendrin



**Figure 7.** pH<sub>ASL</sub> response to WNK463 in TNF $\alpha$ /IL-17-treated CF epithelia. Primary cultures of differentiated CF epithelia were treated with TNF $\alpha$  (10 ng/ml) and IL-17 (20 ng/ml) for 48 hours. (*A*) Changes in *WNK* gene expression revealed by bulk RNA-seq (*n*=6). TPM = transcripts per million. (*B*) *WNK1* and *WNK2* mRNA expression measured using qRT-PCR (*n*=5). (*C*) Immunostaining for WNK1 and WNK2 in control and TNF $\alpha$ /IL-17-treated CF epithelia. Scale bar, 5  $\mu$ m. (*D*) Intensity of WNK1 or WNK2 immunolabeling quantitated as integrated density using imageJ software (*n*=5–6). (*E* and *F*) pH<sub>ASL</sub> responses in TNF $\alpha$ /IL-17-treated CF epithelia. WNK463 (10  $\mu$ M) or bumetanide (100  $\mu$ M) were applied for 2 hours before pH<sub>ASL</sub> measurement (*n*=6–8). Each data point represents an epithelium from a different donor. Data are shown as mean ± SEM. Statistical significance was tested using paired Student's *t* test (*A*, *B*, *D*, and *F*) or ANOVA with *post hoc* Tukey's test (*E*). \**P*<0.05, \*\**P*<0.01, and \*\*\*\**P*<0.0001.

expression and reducing WNK2 expression. Whether WNK kinases regulate apical expression or activity of pendrin in cytokine-treated airway epithelia remains to be determined. Some reports have suggested an interaction between pendrin and apical anion channels that may increase activity of both transporters (72); additional studies are needed to fully understand whether WNK kinases modulate such interactions.

WNK kinases have an ATP-binding site that is unique among protein kinases, and

WNK463 targets this site. Previous studies have found WNK463 to be highly selective (48), but it is possible that higher doses may also affect other targets. To confirm the effect of reducing WNK activity on  $pH_{ASL}$ , we used two orthogonal approaches (i.e., pharmacologic inhibition and gene knockdown). Moreover, inhibiting downstream WNK targets (i.e., SPAK/OSR1 and NKCC1) also increased  $pH_{ASL}$ . Overall, these results point to a key role for the WNK signaling pathway in controlling airway  $HCO_3^-$  secretion and  $pH_{ASL}$ .

This study has several advantages. First, we studied primary cultures of differentiated human airway epithelia from both CF and non-CF genotypes. Second, to account for biological variability, we included epithelia from multiple human donors. Third, we measured pH<sub>ASL</sub> under thin-film conditions without adding additional apical fluid. Fourth, in testing our hypothesis, we used a combination of pharmacologic, transcriptomic, gene silencing, protein immunolabeling, and electrophysiologic approaches. Fifth, although all studies and interventions were performed in primary cultures of differentiated airway epithelia, a preliminary study in established human airway epithelial cell lines, NuLi-1 and CuFi-4, yielded similar results. Finding that WNK signaling is active in these epithelia enables their use as models for studying WNK signaling.

This study also has limitations. First, we used human airway epithelia as an in vitro model, and assessing WNK kinase inhibition in vivo may be of value. However, interpretation of in vivo effects may be complicated by the fact that WNK kinases are expressed broadly in epithelial and nonepithelial cells (42, 43). Newer animal models with tissue- or cell-specific WNK knockouts might help further elucidate roles of WNK kinases. Second, we did not identify the transporter directly responsible for apical HCO<sub>3</sub><sup>-</sup> exit. RNA-seq studies show that CF airway epithelia express several non-CFTR HCO<sub>3</sub><sup>-</sup> transporters, including CaCC and SLC26 family members (41, 73), and WNK inhibition may affect more than one simultaneously. Third, inflammation in CF airways is a complex process, and it will be important for future studies to characterize the effects of other proinflammatory mediators (e.g., IL-8, IL-1β, etc.) on WNK signaling.

The results have implications for CF airways. First, previous studies have shown that the abnormally acidic pHASL observed in newborns with CF increases with time and inflammation (74, 75), although not to levels observed in non-CF epithelia studied under comparable conditions (41). As indicated above, our current data, together with previous results, suggest complex regulatory mechanisms are responsible. Second, loop diuretics, which inhibit NKCC, are commonly used to treat heart failure and fluid overload states (76). Yet, to our knowledge, these agents have not been shown to cause adverse airway phenotypes. This study suggests that  $HCO_3^{-1}$  secretion may compensate for any decrease in



**Figure 8.** WNK kinases may regulate the ratio of  $HCO_3^-$  versus  $CI^-$  secretion in CF airway epithelia. Model shows a CF airway epithelial cell in which the absence of CFTR function decreases  $HCO_3^-$  and  $CI^-$  secretion, generates an acidic  $pH_{ASL}$ , and impairs respiratory host defenses. Left panel: WNK1 and WNK2 regulate activity of basolateral NKCC1 (sodium-potassium-chloride cotransporter 1) via intermediate SPAK/OSR1 (Ste20/SPS1-related proline-alanine-rich protein kinase/oxidative stress responsive 1 kinase). NKCC1 imports  $CI^-$  into the cell.  $CI^-$  and  $HCO_3^-$  exit from the cell across the apical membrane via channels and/or transporters whose identity and quantitative contributions are uncertain (indicated by question marks). Right panel: reducing WNK kinase activity, inhibiting NKCC1, and eliminating  $CI^-$  lower the intracellular chloride concentration and transepithelial  $CI^-$  secretion. At the same time, these interventions increase  $HCO_3^-$  secretion, raise  $pH_{ASL}$ , and improve CF host defenses. We speculate that intracellular CI<sup>-</sup> acts as a signaling molecule that regulates apical and/or basolateral  $HCO_3^-$  transporters. Some features of this model are tentative at present and are opportunities for future research. See text for details.

loop-sensitive Cl<sup>-</sup> secretion and preserve, if not augment, host defenses (77). Third, by enhancing respiratory host defense, WNK inhibition might be a potential therapeutic target in CF and possibly in acquired CFTR dysfunction, such as that induced by cigarette smoking (78). Although WNK463 produced adverse effects in a rat model of hypertension (48), it is a nonselective WNK kinase inhibitor. Interestingly, WNK2 has a more restricted tissue expression than the ubiquitous WNK1, it is detected in airway epithelial cell types relevant for anion secretion, and its knockdown alkalinizes CF ASL. Thus, selective WNK2 inhibitors, inhibitors of downstream SPAK/OSR1 kinases, or inhibitors restricted to the airways might be pursued as potential CF therapeutics.

<u>Author disclosures</u> are available with the text of this article at www.atsjournals.org.

**Acknowledgment:** The authors thank the University of Iowa *In Vitro* Models and Cell Culture Core and the Genomics Division of the Iowa Institute of Human Genetics for technical assistance.

#### References

- Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. *Physiol Rev* 1999;79:S3–S22.
- Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers 2015;1:15010.
- Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med 2015;372:1574–1575.
- Poulsen JH, Fischer H, Illek B, Machen TE. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. *Proc Natl Acad Sci USA* 1994;91:5340–5344.
- Tang L, Fatehi M, Linsdell P. Mechanism of direct bicarbonate transport by the CFTR anion channel. J Cyst Fibros 2009;8:115–121.
- Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. *Physiol Rev* 1999;79:S23–S45.
- Widdicombe JH. Airway epithelium. Colloquium series on integrated systems physiology #36. San Rafael, CA: Morgan & Claypool Life Sciences; 2013.
- Haq IJ, Gray MA, Garnett JP, Ward C, Brodlie M. Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. *Thorax* 2016;71:284–287.
- Verkman AS, Song Y, Thiagarajah JR. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. *Am J Physiol Cell Physiol* 2003;284:C2–C15.
- Gustafsson JK, Ermund A, Ambort D, Johansson ME, Nilsson HE, Thorell K, et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med 2012;209:1263–1272.
- Zajac M, Dreano E, Edwards A, Planelles G, Sermet-Gaudelus I. Airway surface liquid pH regulation in airway epithelium current understandings and gaps in knowledge. *Int J Mol Sci* 2021;22:3384.

- Tang XX, Ostedgaard LS, Hoegger MJ, Moninger TO, Karp PH, McMenimen JD, *et al.* Acidic pH increases airway surface liquid viscosity in cystic fibrosis. *J Clin Invest* 2016;126:879–891.
- Pezzulo AA, Tang XX, Hoegger MJ, Abou Alaiwa MH, Ramachandran S, Moninger TO, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. *Nature* 2012;487:109–113.
- 14. Abou Alaiwa MH, Reznikov LR, Gansemer ND, Sheets KA, Horswill AR, Stoltz DA, et al. pH modulates the activity and synergism of the airway surface liquid antimicrobials β-defensin-3 and LL-37. Proc Natl Acad Sci USA 2014;111:18703–18708.
- Simonin J, Bille E, Crambert G, Noel S, Dreano E, Edwards A, *et al.* Airway surface liquid acidification initiates host defense abnormalities in cystic fibrosis. *Sci Rep* 2019;9:6516.
- Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. *Lancet* 2008;372:415–417.
- Nakayama K, Jia YX, Hirai H, Shinkawa M, Yamaya M, Sekizawa K, et al. Acid stimulation reduces bactericidal activity of surface liquid in cultured human airway epithelial cells. Am J Respir Cell Mol Biol 2002; 26:105–113.
- Birket SE, Davis JM, Fernandez CM, Tuggle KL, Oden AM, Chu KK, et al. Development of an airway mucus defect in the cystic fibrosis rat. *JCI Insight* 2018;3:97199.
- Shah VS, Meyerholz DK, Tang XX, Reznikov L, Abou Alaiwa M, Ernst SE, *et al.* Airway acidification initiates host defense abnormalities in cystic fibrosis mice. *Science* 2016;351:503–507.
- Abou Alaiwa MH, Launspach JL, Sheets KA, Rivera JA, Gansemer ND, Taft PJ, et al. Repurposing tromethamine as inhaled therapy to treat CF airway disease. JCI Insight 2016;1:87535.
- Muraglia KA, Chorghade RS, Kim BR, Tang XX, Shah VS, Grillo AS, et al. Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia. *Nature* 2019;567:405–408.

- Sindić A, Sussman CR, Romero MF. Primers on molecular pathways: bicarbonate transport by the pancreas. *Pancreatology* 2010;10:660–663.
- Fischer H, Widdicombe JH. Mechanisms of acid and base secretion by the airway epithelium. J Membr Biol 2006;211:139–150.
- 24. Cordat E, Casey JR. Bicarbonate transport in cell physiology and disease. *Biochem J* 2009;417:423–439.
- Alka K, Casey JR. Bicarbonate transport in health and disease. *IUBMB* Life 2014;66:596–615.
- Lee MG, Ohana E, Park HW, Yang D, Muallem S. Molecular mechanism of pancreatic and salivary gland fluid and HCO3 secretion. *Physiol Rev* 2012;92:39–74.
- 27. Shah VS, Chivukula RR, Lin B, Waghray A, Rajagopal J. Cystic fibrosis and the cells of the airway epithelium: what are ionocytes and what do they do? *Annu Rev Pathol* 2022;17:23–46.
- 28. Kunzelmann K, Schreiber R, Hadorn HB. Bicarbonate in cystic fibrosis. *J Cyst Fibros* 2017;16:653–662.
- Li H, Salomon JJ, Sheppard DN, Mall MA, Galietta LJ. Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport. *Curr Opin Pharmacol* 2017;34:91–97.
- Shekarabi M, Zhang J, Khanna AR, Ellison DH, Delpire E, Kahle KT. Wnk kinase signaling in ion homeostasis and human disease. *Cell Metab* 2017;25:285–299.
- Park S, Hong JH, Ohana E, Muallem S. The WNK/SPAK and IRBIT/PP1 pathways in epithelial fluid and electrolyte transport. *Physiology* (*Bethesda*) 2012;27:291–299.
- Angyal D, Bijvelds MJC, Bruno MJ, Peppelenbosch MP, de Jonge HR. Bicarbonate transport in cystic fibrosis and pancreatitis. *Cells* 2021;11:54.
- Yang D, Li Q, So I, Huang CL, Ando H, Mizutani A, *et al.* IRBIT governs epithelial secretion in mice by antagonizing the WNK/SPAK kinase pathway. *J Clin Invest* 2011;121:956–965.
- Park HW, Nam JH, Kim JY, Namkung W, Yoon JS, Lee JS, et al. Dynamic regulation of CFTR bicarbonate permeability by [Cl-]i and its role in pancreatic bicarbonate secretion. *Gastroenterology* 2010;139: 620–631.
- 35. Kim Y, Jun I, Shin DH, Yoon JG, Piao H, Jung J, et al. Regulation of CFTR bicarbonate channel activity by WNK1: implications for pancreatitis and CFTR-related disorders. *Cell Mol Gastroenterol Hepatol* 2020;9:79–103.
- Dorwart MR, Shcheynikov N, Wang Y, Stippec S, Muallem S. SLC26A9 is a Cl(-) channel regulated by the WNK kinases. *J Physiol* 2007;584: 333–345.
- Karp PH, Moninger TO, Weber SP, Nesselhauf TS, Launspach JL, Zabner J, et al. An in vitro model of differentiated human airway epithelia: methods for establishing primary cultures. *Methods Mol Biol* 2002;188:115–137.
- Zabner J, Karp P, Seiler M, Phillips SL, Mitchell CJ, Saavedra M, et al. Development of cystic fibrosis and noncystic fibrosis airway cell lines. *Am J Physiol Lung Cell Mol Physiol* 2003;284:L844–L854.
- Zabner J, Smith JJ, Karp PH, Widdicombe JH, Welsh MJ. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. *Mol Cell* 1998;2:397–403.
- Ramachandran S, Krishnamurthy S, Jacobi AM, Wohlford-Lenane C, Behlke MA, Davidson BL, *et al.* Efficient delivery of RNA interference oligonucleotides to polarized airway epithelia in vitro. *Am J Physiol Lung Cell Mol Physiol* 2013;305:L23–L32.
- 41. Rehman T, Karp PH, Tan P, Goodell BJ, Pezzulo AA, Thurman AL, et al. Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators. J Clin Invest 2021;131:150398.
- 42. McCormick JA, Ellison DH. The WNKs: atypical protein kinases with pleiotropic actions. *Physiol Rev* 2011;91:177–219.
- GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* 2015;348:648–660.
- 44. Plasschaert LW, Žilionis R, Choo-Wing R, Savova V, Knehr J, Roma G, et al. A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. *Nature* 2018;560:377–381.
- Montoro DT, Haber AL, Biton M, Vinarsky V, Lin B, Birket SE, et al. A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. *Nature* 2018;560:319–324.

- 46. Okuda K, Dang H, Kobayashi Y, Carraro G, Nakano S, Chen G, *et al.* Secretory cells dominate airway cftr expression and function in human airway superficial epithelia. *Am J Respir Crit Care Med* 2021;203: 1275–1289.
- Barbry P, Marcet B, Caballero I. Where is the cystic fibrosis transmembrane conductance regulator? *Am J Respir Crit Care Med* 2021;203:1214–1216.
- Yamada K, Park HM, Rigel DF, DiPetrillo K, Whalen EJ, Anisowicz A, et al. Small-molecule WNK inhibition regulates cardiovascular and renal function. Nat Chem Biol 2016;12:896–898.
- 49. Lu DC, Hannemann A, Wadud R, Rees DC, Brewin JN, Low PS, et al. The role of WNK in modulation of KCl cotransport activity in red cells from normal individuals and patients with sickle cell anaemia. *Pflugers Arch* 2019;471:1539–1549.
- Mayes-Hopfinger L, Enache A, Xie J, Huang CL, Köchl R, Tybulewicz VLJ, et al. Chloride sensing by WNK1 regulates NLRP3 inflammasome activation and pyroptosis. Nat Commun 2021;12:4546.
- Zhang J, Deng X, Kahle KT. Leveraging unique structural characteristics of WNK kinases to achieve therapeutic inhibition. *Sci Signal* 2016;9:e3.
- Alessi DR, Zhang J, Khanna A, Hochdörfer T, Shang Y, Kahle KT. The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters. Sci Signal 2014;7:re3.
- AlAmri MA, Kadri H, Alderwick LJ, Simpkins NS, Mehellou Y. Rafoxanide and closantel inhibit spak and osr1 kinases by binding to a highly conserved allosteric site on their c-terminal domains. *ChemMedChem* 2017;12:639–645.
- Wine JJ, Hansson GC, König P, Joo NS, Ermund A, Pieper M. Progress in understanding mucus abnormalities in cystic fibrosis airways. J Cyst Fibros 2018;17:S35–S39.
- Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. *Cell* 1996;85:229–236.
- Kahle KT, Rinehart J, Lifton RP. Phosphoregulation of the Na-K-2Cl and K-Cl cotransporters by the WNK kinases. *Biochim Biophys Acta* 2010; 1802:1150–1158.
- Huang CL, Yang SS, Lin SH. Mechanism of regulation of renal ion transport by WNK kinases. *Curr Opin Nephrol Hypertens* 2008;17:519–525.
- Welsh MJ. Intracellular chloride activities in canine tracheal epithelium: direct evidence for sodium-coupled intracellular chloride accumulation in a chloride-secreting epithelium. J Clin Invest 1983;71:1392–1401.
- Willumsen NJ, Davis CW, Boucher RC. Intracellular CI- activity and cellular CI- pathways in cultured human airway epithelium. *Am J Physiol* 1989;256:C1033–C1044.
- Willumsen NJ, Davis CW, Boucher RC. Cellular CI- transport in cultured cystic fibrosis airway epithelium. Am J Physiol 1989;256:C1045–C1053.
- 61. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009;180: 146–152.
- Schultz A, Stick S. Early pulmonary inflammation and lung damage in children with cystic fibrosis. *Respirology* 2015;20:569–578.
- Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, *et al.*; AREST CF Investigators. Risk factors for bronchiectasis in children with cystic fibrosis. *N Engl J Med* 2013;368:1963–1970.
- Lukacs NW, Strieter RM, Chensue SW, Widmer M, Kunkel SL. TNFalpha mediates recruitment of neutrophils and eosinophils during airway inflammation. *J Immunol* 1995;154:5411–5417.
- Karpati F, Hjelte FL, Wretlind B. TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand J Infect Dis 2000;32:75–79.
- 66. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growthrelated oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005;175:404–412.
- Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011;184:252–258.

- 68. Rehman T, Thornell IM, Pezzulo AA, Thurman AL, Romano Ibarra GS, Karp PH, et al. TNFα and IL-17 alkalinize airway surface liquid through CFTR and pendrin. Am J Physiol Cell Physiol 2020;319:C331–C344.
- Lüscher BP, Vachel L, Ohana E, Muallem S. Cl<sup>-</sup> as a bona fide signaling ion. Am J Physiol Cell Physiol 2020;318:C125–C136.
- Shcheynikov N, Son A, Hong JH, Yamazaki O, Ohana E, Kurtz I, et al. Intracellular CI- as a signaling ion that potently regulates Na+/HCO3transporters. Proc Natl Acad Sci USA 2015;112:E329–E337.
- Yamaguchi M, Steward MC, Smallbone K, Sohma Y, Yamamoto A, Ko SB, *et al.* Bicarbonate-rich fluid secretion predicted by a computational model of guinea-pig pancreatic duct epithelium. *J Physiol* 2017;595:1947–1972.
- 72. Kim D, Huang J, Billet A, Abu-Arish A, Goepp J, Matthes E, et al. Pendrin mediates bicarbonate secretion and enhances cystic fibrosis transmembrane conductance regulator function in airway surface epithelia. Am J Respir Cell Mol Biol 2019;60:705–716.
- 73. Carraro G, Langerman J, Sabri S, Lorenzana Z, Purkayastha A, Zhang G, et al. Transcriptional analysis of cystic fibrosis airways at single-cell

resolution reveals altered epithelial cell states and composition. *Nat Med* 2021;27:806–814.

- Schultz A, Puvvadi R, Borisov SM, Shaw NC, Klimant I, Berry LJ, et al. Airway surface liquid pH is not acidic in children with cystic fibrosis. Nat Commun 2017;8:1409.
- Abou Alaiwa MH, Beer AM, Pezzulo AA, Launspach JL, Horan RA, Stoltz DA, *et al.* Neonates with cystic fibrosis have a reduced nasal liquid pH: a small pilot study. *J Cyst Fibros* 2014;13:373–377.
- Oh SW, Han SY. Loop diuretics in clinical practice. *Electrolyte Blood* Press 2015;13:17–21.
- Grubb BR, Pace AJ, Lee E, Koller BH, Boucher RC. Alterations in airway ion transport in NKCC1-deficient mice. *Am J Physiol Cell Physiol* 2001; 281:C615–C623.
- 78. Raju SV, Lin VY, Liu L, McNicholas CM, Karki S, Sloane PA, et al. The cystic fibrosis transmembrane conductance regulator potentiator ivacaftor augments mucociliary clearance abrogating cystic fibrosis transmembrane conductance regulator inhibition by cigarette smoke. *Am J Respir Cell Mol Biol* 2017;56:99–108.